A Phase III Trial of Perioperative Versus Adjuvant Chemotherapy for Resectable Pancreatic Cancer (A021806)

The purpose of this study is to attempt to determine if the chance of pancreatic cancer staying away increases by giving chemotherapy before or after surgery.

The study hopes to help find if this approach is better or worse than the usual approach for pancreatic cancer. The usual approach is defined as care most people get for removable pancreatic cancer.

What is the usual approach to my pancreatic cancer?

The usual approach for patients who are not in a study is treatment with surgery, chemotherapy, or radiation therapy. Sometimes, combinations of these treatments are used. There are several chemotherapy drugs approved by the Food and Drug Administration (FDA) that are commonly used. These treatments can reduce symptoms and may stop the tumor from growing for a few months or longer. The usual approach is proven to help patients live longer.

This trial is part of the National Clinical Trials Network (NCTN) program, which is sponsored by the National Cancer Institute (NCI). The trial will be led by Alliance for Clinical Trials in Oncology with the participation of the network of NCTN organizations: NRG Oncology; ECOG-ACRIN Medical Group; and SWOG.

Inova Schar Cancer Institute
8081 Innovation Park Drive
Fairfax, VA 22031
A Department of Inova Fairfax Hospital

Inova Fairfax Hospital
3300 Gallows Road
Falls Chruch, VA 22042

• Adults 18 years of age or older
• Appropriate candidate for curative-intent pancreatectomy by surgeon
• Additional eligibility in protocol

• Prior radiation therapy, chemotherapy, targeted therapy, investigational therapy, or surgery for pancreatic cancer
• Known Gilbert’s Syndrome or known homozygosity for UGAT1A1*28 polymorphism
• Pregnancy/nursing
• Additional ineligibility in protocol

For additional information, please see: https://www.clinicaltrials.gov/ct2/show/NCT04340141